Cenix BioScience GmbH
Tatzberg 47
Dresden
01307
Germany
Tel: 49-351-41730
Fax: 49-351-4173109
Website: http://www.cenix.com/
Email: info@cenix.com
20 articles about Cenix BioScience GmbH
-
Cenix BioScience GmbH Signs Research Service Agreement With Bayer Pharma S.A.
5/5/2014
-
Cenix BioScience GmbH and Debiopharm Collaborate to Identify Predictive Biomarkers
5/23/2013
-
Cytoo, Cenix BioScience GmbH and Academic Collaborators Bioquant, EPFL and FTMC Receive a 4 Million€ EU FP7 Grant to Launch MEHTRICS Consortium
12/12/2011
-
Cenix BioScience GmbH Signs RNAi Research Agreement with SYGNIS Pharma AG
11/17/2011
-
Cenix BioScience GmbH Grows, Establishing New R&D Subsidiary in Flanders, Belgium
1/12/2011
-
Cenix BioScience GmbH Expands Relationship with AstraZeneca AB, Signing Multi-Project Research Agreement
6/15/2009
-
Cenix BioScience GmbH Follows up Successful RNAi-Based Target Discovery Screens with Target Validation Study for AstraZeneca PLC
3/19/2009
-
Cenix BioScience GmbH Signs Research Agreement with Boehringer Ingelheim Corporation for RNAi-Based Target Discovery
2/2/2009
-
InteRNA Technologies and Cenix BioScience GmbH Ink Research Agreement for miRNA Drug Discovery
11/17/2008
-
Instituto de Medicina Molecular, Cenix BioScience GmbH, and Alnylam Pharmaceuticals Discover New Targets in Malaria Infection with RNAi Technology
11/11/2008
-
New Pathway For Malaria Infection Discovered by Cenix BioScience GmbH, Alnylam Pharmaceuticals and Instituto de Medicina Molecular Researchers
9/15/2008
-
Instituto de Medicina Molecular, Cenix BioScience GmbH, and Alnylam Pharmaceuticals Discover New Pathway for Malaria Infection
9/11/2008
-
Cenix BioScience GmbH Signs Research Agreement with Regulus Therapeutics (JOBS) for miRNA-Targeted Drug Discovery
7/21/2008
-
Following Success of Pilot, Cenix BioScience GmbH Takes on Second RNAi-Based Target Validation Project for CellCentric Ltd.
7/1/2008
-
Cenix BioScience GmbH and CellCentric Ltd. Second RNAi-Based Target Validation Project
7/1/2008
-
Cenix BioScience GmbH and CellCentric Ltd. Sign Framework Research Agreement for RNAi-Based Target Validation
3/20/2008
-
Cenix BioScience GmbH Signs Framework Research Agreement with AstraZeneca PLC for RNAi-Based Drug Discovery
3/19/2008
-
Cenix BioScience GmbH Expands Usage of Definiens Technology in High-Content Screening
2/13/2008
-
Cenix BioScience GmbH And Merck KGaA Sign Framework Agreement For RNAi-Based Drug Discovery
9/27/2006
-
Cenix BioScience GmbH And Schering AG Enter Into Agreement On Multiple RNAi-Based Target Validation Projects
10/25/2005